Study shows rituximab effective in treating chronic graft-versus-host disease
23rd Mar 2006, 21:58 GMT
A study by Dana-Farber Cancer Institute researchers offers the strongest evidence yet of the effectiveness of a novel therapy for chronic graft-versus-host disease (GVHD), a potentially life-threatening complication of donor bone marrow and stem cell transplants. Researchers found that rituximab reduced the severity of chronic GVHD in 70 percent of the study participants who completed at least one course of treatment, including two who experienced complete remissions of symptoms.
Study shows rituximab effective in treating chronic graft-versus-host disease related news:
- Study shows rituximab effective in treating chronic graft-versus-host disease — KeralaNext: Latest News
- Rituxan Promising for Chronic Graft-versus-Host Disease — MedPage Today.com Latest Headlines
- Controversial drug 'effective' — Scotsman.com News - Health
- Drug shown to provide much needed alternative therapy for chronic shoulder pain — EurekAlert! - Medicine and Health
- Thalidomide shows promise for ovarian cancer treatment — News & Features from Minnesota Public Radio
- Levitra proves effective in hypertension patients — Pharmaceutical Business Review Latest News
- Scientists Discover That Widely Available Drug Also Helps Fight Kidney Disease — ScienceDaily Headlines
- Raloxifene shows potential benefits in treating prostate cancer — News-Medical News Feed
- Study shows games keep you sane — Lifehacker
- Drugs Benefit Half With Depression, Study Finds — washingtonpost.com - Today's Highlights
Latest news from EurekAlert! - Medicine and Health:
- Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years
- Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data
- UCSD computer scientist wins Young Investigator Award, research on snake venom proteins highlighted
- Why do insects like to eat some plants more than others?
- Opposites do not attract
- Wild gorillas carriers of an SIV virus close to the AIDS virus
- New data show ACTOS (pioglitazone HCl) halted progression of atherosclerosis as indicated by CIMT
- Pourquié lab identifies genes involved in formation of vertebral precursors
- Artificial cornea offers better results for infants, some blind patients
- Healthier kids just the click of a remote away